Literature DB >> 15120465

Estimating medical care costs under conditions of censoring.

M Raikou1, A McGuire.   

Abstract

A number of non-parametric estimators have been proposed to calculate average medical care costs in the presence of censoring. This paper assesses their performance both in terms of bias and efficiency under extreme conditions using a medical dataset which exhibits heavy censoring. The estimators are further investigated using artificially generated data. Their variances are derived from analytic formulae based on the estimators' asymptotic properties and these are compared to empirically derived bootstrap estimates. The analysis revealed various performance patterns ranging from generally stable estimators under all conditions considered to estimators which become increasingly unstable with increasing levels of censoring. The bootstrap estimates of variance were consistent with the analytically derived asymptotic variance estimates. Of the two estimators that performed best, one imposes restrictions on the censoring distribution while the other is not restricted by the censoring pattern and on this basis the second may be preferred. Copyright 2003 Elsevier B.V.

Mesh:

Year:  2004        PMID: 15120465     DOI: 10.1016/j.jhealeco.2003.07.002

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  11 in total

1.  Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis.

Authors:  V F Fragoulakis; A G Pallis; D K Kaitelidou; N M Maniadakis; V G Georgoulias
Journal:  Lung Cancer (Auckl)       Date:  2012-07-16

2.  Estimating 'costs' for cost-effectiveness analysis.

Authors:  Alec Miners
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Nonparametric inference for median costs with censored data.

Authors:  Hongwei Zhao; Chen Zuo; Shuai Chen; Heejung Bang
Journal:  Biometrics       Date:  2012-02-24       Impact factor: 2.571

4.  Estimating incremental cost-effectiveness ratios and their confidence intervals with different terminating events for survival time and costs.

Authors:  Shuai Chen; Hongwei Zhao
Journal:  Biostatistics       Date:  2013-02-19       Impact factor: 5.899

5.  Some insight on censored cost estimators.

Authors:  H Zhao; Y Cheng; H Bang
Journal:  Stat Med       Date:  2011-07-11       Impact factor: 2.373

6.  Estimating mean total costs in the presence of censoring: a comparative assessment of methods.

Authors:  Tracey A Young
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Average cost-effectiveness ratio with censored data.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

8.  Propensity score and doubly robust methods for estimating the effect of treatment on censored cost.

Authors:  Jiaqi Li; Elizabeth Handorf; Justin Bekelman; Nandita Mitra
Journal:  Stat Med       Date:  2015-12-17       Impact factor: 2.373

9.  Techniques for estimating health care costs with censored data: an overview for the health services researcher.

Authors:  Harindra C Wijeysundera; Xuesong Wang; George Tomlinson; Dennis T Ko; Murray D Krahn
Journal:  Clinicoecon Outcomes Res       Date:  2012-06-01

10.  Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.

Authors:  Robert I Griffiths; Michelle L Gleeson; Joseph Mikhael; Mark D Danese
Journal:  J Cancer Epidemiol       Date:  2012-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.